Similar articles

• Advances in specific immunotherapy for prostate cancer.

  Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M. Kiessling A, et al. Eur Urol. 2008 Apr;53(4):694-708. doi: 10.1016/j.eururo.2007.11.043. Epub 2007 Nov 26. Eur Urol. 2008. PMID: 18061335 Review.
• The immunotherapy of prostate and bladder cancer.

  Totterman TH, Loskog A, Essand M. Totterman TH, et al. BJU Int. 2005 Oct;96(5):728-35. doi: 10.1111/j.1464-410X.2005.05772.x. BJU Int. 2005. PMID: 16144528
• Immunotherapeutics in development for prostate cancer.

  Harzstark AL, Small EJ. Harzstark AL, et al. Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Epub 2009 Apr 2. Oncologist. 2009. PMID: 19342474 Review.
• Target molecules in specific immunotherapy against prostate cancer.

  Harada M, Noguchi M, Itoh K. Harada M, et al. Int J Clin Oncol. 2003 Aug;8(4):193-9. doi: 10.1007/s10147-003-0332-x. Int J Clin Oncol. 2003. PMID: 12955573 Review.
• Harnessing immunity for cancer marker discovery.

  Hanash S. Hanash S. Nat Biotechnol. 2003 Jan;21(1):37-8. doi: 10.1038/nbt0103-37. Nat Biotechnol. 2003. PMID: 12511908 No abstract available.